AbbVie (ABBV) Tops Q4 EPS by 2c, Beats on Revenue; Offers FY24 EPS Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Abbvie (ABBV) PT Raised to $180 at Goldman Sachs
February 5, 2024 5:58 AM ESTGoldman Sachs analyst Chris Shibutani raised the price target on Abbvie (NYSE: ABBV) to $180.00 (from $173.00) while maintaining a Buy rating.
The analyst comments "4Q23 results and management's commentary on the FY24 and longer-term outlook strengthen our confidence in the potential for ABBV shares to continue to outperform. Across the company's Immunology... More
AbbVie (ABBV) tops Q4 earnings, revenue consensus estimate
February 2, 2024 8:37 AM ESTAbbVie (NYSE: ABBV) shares edged around 1% higher early Friday after the company reported earnings before the open, topping fourth-quarter profit and revenue expectations.
The American pharmaceutical company reported fourth-quarter adjusted earnings of $2.79 per share, $0.02 better than the analyst estimate of $2.77. Meanwhile, revenue... More
